Agree completely.
NEU had a ridiculous jump today on phase 2 results.
We sit at 240 mill cap on a virtually approved FDA product selling in overseas markets, with considerable growth in prescription uptake.
BOT has a huge pipeline behind it.
Given the attention NEU has bought to the biotech sector, surely BOT has a huge re rate ahead of it.
Agree completely.NEU had a ridiculous jump today on phase 2...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $346.5M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.0¢ | 21.5¢ | $556.8K | 2.564M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 188599 | 5 |
View Market Depth
| Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
21.8¢ |
Change
0.000 ( 1.09 %) |
||||
| Open | High | Low | Volume | ||
| 22.0¢ | 22.0¢ | 21.5¢ | 1397313 | ||
| Last updated 15.59pm 30/04/2024 ? | |||||
| BOT (ASX) Chart |